Docetaxel - Starpharma

Drug Profile

Docetaxel - Starpharma

Alternative Names: Dendrimer docetaxel; DEP™-Docetaxel

Latest Information Update: 06 Oct 2015

Price : $50

At a glance

  • Originator Starpharma
  • Developer Monash University; Starpharma
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 30 Sep 2015 Pharmacodynamics data from preclinical trials in Solid tumours released by Starpharma
  • 22 Jan 2014 Phase-I clinical trials in Solid tumours in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top